Ironwood Pharmaceuticals is trading 5% down at $4.43 today as the stock pulls back following a Form 4 filing disclosing insider share sales on July 9, 2026.
- The decline follows a period of strong recent gains driven by upbeat Q1 2026 results and maintained full-year guidance.
- While insider sales can weigh on short-term sentiment, fundamentals remain supported by robust growth in LINZESS.
- Management has reiterated its full-year outlook, suggesting the company's core business trajectory remains intact despite the share price volatility.